Integrative Oncology | RGCC founder and genetics pioneer Dr Ioannis Papasotiriou hosted a two-day symposium in Melbourne, Australia. Take a look at the range of subjects we covered at the gathering and hear from some of the delegates who took part.
On January 2020 took place the in Tokyo the Clinical CTC Seminar. This event was promoted by Dr. Atsushi Yanagisawa, Chairman of the Intravenous Therapy Study Group and Dr. Kunihiro Kitamura, Director of the Kitamura Clinic in Fukuoka. Dr. Ioannis Papasotiriou was one of the basics lecturer.
Yes. Onconomics and Onconomics Plus tests can be used for Ras-Raf-MEK-Erk, dabrafenib, vemurafenib, c-Jun, C-Fos, trametinib and sorafenib.
Can the Oncotrace test differentiate between benign and malignant tumour cells?
Yes. The Oncotrace test provides information about the presence of circulating tumour cells, their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.
I have a patient whose specific tumour appears to have resisting populations because of the overexpression of the MDR1 gene. This can be reversed by the use of inhibitors of ABG2 pumps. What do I do?
In this case, a patient could proceed with ketoconazole as a first-line treatment, and verapanib as a second-line treatment. Verapanib can contribute to a fall in blood pressure.
Didn't find an answer to your question? Contact us directly.